These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33721729)

  • 1. A human bispecific neutralization antibody against four serotypes of dengue virus.
    Wang R; Lu J; Chen L; Yu Y; Yang Z
    Virology; 2021 Jun; 558():49-56. PubMed ID: 33721729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion.
    Shi X; Deng Y; Wang H; Ji G; Tan W; Jiang T; Li X; Zhao H; Xia T; Meng Y; Wang C; Yu X; Yang Y; Li B; Qin ED; Dai J; Qin CF; Guo Y
    MAbs; 2016; 8(3):574-84. PubMed ID: 26905804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.
    Lingemann M; Amaro-Carambot E; Lamirande EW; Pierson TC; Whitehead SS
    J Virol; 2024 Jul; 98(7):e0068124. PubMed ID: 38953379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
    Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
    Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia.
    Balingit JC; Denis D; Suzuki R; Hayati RF; Ngwe Tun MM; Takamatsu Y; Masyeni S; Sasmono RT; Morita K
    Virus Res; 2024 Oct; 348():199445. PubMed ID: 39089369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy.
    Flingai S; Plummer EM; Patel A; Shresta S; Mendoza JM; Broderick KE; Sardesai NY; Muthumani K; Weiner DB
    Sci Rep; 2015 Jul; 5():12616. PubMed ID: 26220099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient.
    Schieffelin JS; Costin JM; Nicholson CO; Orgeron NM; Fontaine KA; Isern S; Michael SF; Robinson JE
    Virol J; 2010 Feb; 7():28. PubMed ID: 20132551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection.
    Auerswald H; Kann S; Klepsch L; Hülsemann J; Rudnik I; Schreiber S; Buchy P; Schreiber M
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human monoclonal antibody to neutralize all four serotypes of dengue virus derived from patients at the convalescent phase of infection.
    Lu J; Chen L; Du P; Guo J; Wang X; Jiang Y; Yu Y; Wang R; Yang Z
    Virology; 2022 Nov; 576():74-82. PubMed ID: 36183498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
    Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
    J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.